Welldoc’s chronic disease portfolio grows with new features to support people with both type 1 and type 2 diabetes Columbia, MD – February 6, 2019 – Welldoc®, a leading digital health company, announced today its filing at the end of 2018 with the U.S. Food and Drug Administration (FDA) for 510(k) clearance of additional features…
Type: Press Release
Columbia, MD – January 7, 2019 – Welldoc®, a leading digital health company, announced today that it has secured a technology patent (based on U.S. Patent Application No. 15/923,010) from the United States Patent and Trademark Office for the Software Engine Technology that powers its BlueStar® digital therapeutic. “The awarding of this tenth technology patent…
Columbia, Maryland, November 9, 2018 – Welldoc®, a leading digital health company, announced today that its executives and digital health, diabetes and healthcare industry thought leaders will speak and/or participate in events at prominent diabetes and healthcare conferences this Fall. The list of events is as follows: 18th Annual Diabetes Technology Meeting November 8-10, 2018, Bethesda…
Columbia, MD October 15, 2018 – Welldoc® today announced that one of the world’s leading academic medical centers is moving into Phase 2 for ongoing Quality Improvement research of BlueStar, its FDA-cleared digital therapeutic, in the treatment of patients with type 2 diabetes within primary care. Principal investigator Daniel Henderson, MD, MPH, a primary care…
Baltimore, MD – August 30, 2018 – Welldoc®, a leading digital health company revolutionizing chronic disease management to help transform lives through the use of its digital therapeutics, announced today that Daniel Garrett, a digital health transformation consultant and recently retired partner at PricewaterhouseCoopers (PwC), has been appointed to Welldoc’s Board of Directors. “Dan brings…
– Malinda Peeples, RN, MS, CDE, Welldoc’s Vice President of Clinical Services, Programs and Research Recognized Today with AADE Allene Van Son Distinguished Service Award – Welldoc®, a leading digital health company revolutionizing chronic disease management to help transform lives through the use of its digital therapeutics, today announces its broad involvement at the American…
-BlueStar Provides One-Stop Solution for Managing Multiple Chronic Conditions – Welldoc®, a leading digital health company, today announces hypertension and weight management solutions integrated within its digital therapeutic app for type 2 diabetes, BlueStar®. Later this year, Welldoc will launch its stand-alone product for individuals living with hypertension (high blood pressure) and stand-alone products are…
– Findings Shared During Poster Presentation at the American Diabetes Association’s (ADA) 78th Scientific Sessions – Welldoc®, a leading digital health company revolutionizing chronic disease management to help transform lives through the use of its digital therapeutics, today announced results from an innovative economic analysis that demonstrated the potential for significant healthcare cost savings with…
Allegheny Health Network will spearhead the evaluation to determine clinical, financial and patient experience outcomes related to BlueStar PITTSBURGH, PA and COLUMBIA, MD – Highmark Health announced today that through its VITAL Innovation Program, a test-and-learn platform, it will be evaluating Welldoc’s® BlueStar® mobile app, an FDA-cleared, proven digital therapeutic for individuals with type 2…
Columbia, Maryland, April 4, 2018 – Welldoc®, a leading digital therapeutics company, announced today that its executives and digital health, diabetes and healthcare industry thought leaders will speak and/or participate in panel discussions at prominent diabetes and healthcare conferences this Spring. The list of events is as follows: Johns Hopkins Clinical Continuing Education Series April…